Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : PRESIDENT GEORGE W. BUSH -- Ignore unavailable to you. Want to Upgrade?

To: greenspirit who wrote (199945)	11/5/2001 1:27:50 AM
From: mr.mark	Read Replies (6) \| Respond to of 769670

michael, that story you have posted has been pretty much debunked as an urbanlegend.... a hoax, that is, false. it's been making the rounds for quite some time. snopes2.com

To: greenspirit who wrote (199945)	11/5/2001 1:37:47 AM
From: Thomas A Watson	Respond to of 769670

America, we build, we create, we solve problems. Drug science goes digital Thanks to the Human Genome Project's tsunami of data, a startling transformation in drug science is about to take place. One-drug-fits-all development strategies may soon look as outdated as one-color automobile manufacturing, as mass drugs give way to miracle drugs tailored to fit the individual patient's DNA profile, or that of the patient's family, or at the very least, his ethnic group. Why are black patients with heart failure more likely to die? Racism? Poverty? Lack of insurance? In a recent issue of the New England Journal of Medicine, researchers think they've spotted a medical answer. Almost everyone who rolls into a hospital with heart failure gets Enalapril, a drug which just turns out to work better in whites than blacks. Pharmacogenomics is the name of a new medical field that exploits such differences in the way individual networks of genes react to particular drugs. Pharmacogenomics allows doctors to separate people into different treatment groups based solely on variations in DNA sequences and then to develop the targeted drugs most likely to work for them. gilder.com tom watson tosiwmee